BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Insight
  • Biologics
Unlocking the potential of RNA therapeutics through innovation and collaboration
White paper
  • Analytical chemistry
Using in vitro release testing (IVRT) to analyse semi-solid topical formulations
Insight
  • Biologics
Enhancing the production of RNA with continuous manufacturing
Fact sheet
  • Drug product
GERTEIS MINI-PACTOR® Advanced dry granulation services
Case study
  • Biologics
Overcoming oncolytic virus therapy production challenges through collaboration
Insight
  • Industry trends
Emerging trends set to impact drug development in 2024
Webinar
  • Biologics
Webinar: ATMPs in focus: Essential CMC strategies for every phase
Insight
  • Drug product
  • Industry trends
Trends set to make an impact on oral solid dose development in 2024
Insight
  • Biologics
Enhancing AAV therapy development and manufacture with a platform approach